Andrew Curtis
Bethlehem,PA
Summary
Results-driven, entrepreneurial life science executive, laser-focused on delivering patient and shareholder value. Demonstrable track record of building new businesses and initiatives across multiple therapeutic areas, specifically in rare diseases and Oncology.
Overview
29
29
years of professional experience
Work History
Chief Business and Strategy Officer
Nerviano Medical Sciences
Nerviano, Italy And Bethlehem, PA
08.2022 - 05.2023
- Led creation of NMS' CRO and CDMO business plans to support out-licensing/sale initiative. CRO sold to Frontage in 2023
- Staffed and trained NMS' nascent Oncology BD team, closing three development agreements in four months.
Vice President, Business Development
GNS Healthcare (now Atria)
Remote
11.2020 - 07.2022
- Focusing on top five pharmaceutical and biotechnology companies, secured six research projects, deploying Atria's causal AI in silico digital twin technology, utilizing proteogenomic, RWE, and patient data to more efficiently design drug and biomarker clinical studies.
Vice President, Business Development
Suda Pharmaceuticals
US And Australia
03.2018 - 12.2019
- Successfully closed two research agreements with Sanofi and Teva to utilize Suda's novel buccal lining reformulation technology, creating a spray mist to more efficiently administer solid oral dose medications.
Head, Corporate Strategy and Business Development
Affimed
US And Germany
01.2015 - 11.2017
- Secured two academic research and commercialization agreements (MD Anderson and Sloan Kettering). Signed an additional research collaboration with a leading immuno-oncology company (unnamed).
- Led the revamp of Affimed's NK antibody portfolio to create a more focused, balanced portfolio of early and mid-stage assets.
Founder
Rising Tide Therapeutics
PA
09.2014 - 01.2015
- In partnership with the Alpha-1/COPD Foundation, founded rare disease newco focused on developing a gene therapy cure for alpha anti-trypsin deficiency. Unable to progress the Company due to technical failures.
Head, External Opportunities
Pfizer Specialty Care
Collegeville, PA
03.2012 - 01.2015
- Led search, evaluation, and transaction team to identify new whitespace and adjacency opportunities.
- Built business cases and Bard presentations for new initiatives in Advanced Wound Healing and Specialty Pain to support existing core Pfizer businesses
Executive Director, R&D Innovation and Strategy
Pfizer BioTherapeutics R&D
Cambridge, MA
02.2010 - 03.2012
- Led team that redesigned Pfizer's biologics research efforts by creating smaller, more focused entrepreneurial research units, by positioning the CSO as the CEO of each therapeutic unit, creating greater autonomy and focus. Led Pfizer's relocation from Alewife to Cambridge's burgeoning biotech community.
- Developed a novel service model newco to provide under-utilized drug development services and capabilities, funding, and assets to VC-backed biotech companies via a co-funded, option-based exit strategy.
Team Lead, Rare Disease and Biosimilar Commercial
Pfizer Established Products
New York, NY
10.2008 - 02.2010
- Led team team developing two new business initiatives for Rare Diseases and Biosimilars. Gained Pfizer Board approval and funding to support initiative.
- Public communication of Pfizer initiative boosted stock value by 2.5% (>$5B)
- In-licensed Protalix's 1st plant cell-based therapy for Gaucher's disease (Elelyso), growing WW market to $1.2B, including accessing Brazil market via annualized $75m tech-transfer
- Acquired FoldRx, acquiring Tafamadis (TTR), launching to exceed $1B
- Constructed an internal pipeline of 12 biosimilar development programs
- Signed deal to license Biocon's five diabetes therapies
US General Manager
Jerini US
New York, NY
02.2006 - 10.2008
- Built and led US commercial team (Medical, Scientific Affairs, Marketing, Reimbursement, Advocacy, etc.), successfully developing Hereditary Angioedema market in preparation for launch of icatibant, ultimately launching to successful annualized sales of ~$650 in US.
Director, US Aricept Marketing
Pfizer
New York, NY
01.2003 - 02.2006
- Led US Aricept team to generate in excess of $1B (2005) for this marginal brand. P&L responsibility.
Director, Advanced Wound Care Commercialization
J&J Ethicon
Bridgewater, NJ
11.2000 - 02.2003
- Led all commercialization and alliance management efforts to support biological wound healing therapy to treat severe burns, wounds, and tissue fillers.
Director, Commercial Development
Genzyme
Cambridge, MA
01.1996 - 02.2000
- Responsible for Genzyme's LSD commercial development of therapies for Pompe's and Fabry's diseases. Led all patient advocacy, pricing, distribution strategies for both programs.
Market Development Associate
Merck
Whitehouse Station, NJ
06.1994 - 04.1996
- Established two Women's Canters of Excellence (St. Barnabas/Overlook Hospital) in support of early osteoporosis detection and treatment with Fosamax.
Education
Master of Arts - Government
Lehigh University
Bethlehem05.1994
Bachelor of Arts - Political Science
Muhlenberg College
Allentown, PA05.1992
Skills
- Team building
- Critical Thinking
- Supervision and leadership
- Decision-Making
- Task Prioritization
- Relationship Building
- Problem-Solving
- Innovation and Entrepreneurship
Affiliations
- NORD Corporate Council
- Alpha-1 Foundation Board
Timeline
Chief Business and Strategy Officer
Nerviano Medical Sciences
08.2022 - 05.2023
Vice President, Business Development
GNS Healthcare (now Atria)
11.2020 - 07.2022
Vice President, Business Development
Suda Pharmaceuticals
03.2018 - 12.2019
Head, Corporate Strategy and Business Development
Affimed
01.2015 - 11.2017
Founder
Rising Tide Therapeutics
09.2014 - 01.2015
Head, External Opportunities
Pfizer Specialty Care
03.2012 - 01.2015
Executive Director, R&D Innovation and Strategy
Pfizer BioTherapeutics R&D
02.2010 - 03.2012
Team Lead, Rare Disease and Biosimilar Commercial
Pfizer Established Products
10.2008 - 02.2010
US General Manager
Jerini US
02.2006 - 10.2008
Director, US Aricept Marketing
Pfizer
01.2003 - 02.2006
Director, Advanced Wound Care Commercialization
J&J Ethicon
11.2000 - 02.2003
Director, Commercial Development
Genzyme
01.1996 - 02.2000
Market Development Associate
Merck
06.1994 - 04.1996
Master of Arts - Government
Lehigh University
Bachelor of Arts - Political Science
Muhlenberg College